BEBP02-054Q LONZA X-VIVO 15  免疫細胞無血清培養(yǎng)基

北京云肽生物科技代理的LONZA X-VIVO 15 免疫細胞培養(yǎng)基（貨號：BEBP02-054Q），作為LONZA zui暢銷的無血清培養(yǎng)基，可為免疫細胞提供營養(yǎng)平衡完善的體外培養(yǎng)環(huán)境，已成功應用于T細胞、造血干細胞、單核細胞、巨噬細胞、CIK、自然殺傷細胞、外周血淋巴細胞、樹突狀細胞、淋巴因子激活殺傷細胞、腫瘤浸潤淋巴細胞、粒細胞的培養(yǎng)中。



LONZA X-VIVO 15 培養(yǎng)基，不含外源生長因子、人工細胞增殖刺激因子、蛋白激酶C刺激劑，所有成分明確，含有重組人胰島素、重組人轉鐵蛋白和白蛋白，并針對腫瘤浸潤淋巴細胞（TIL）的體外無血清培養(yǎng)進行了優(yōu)化，近年來在眾多CAR-T研究中得到使用。




Serum-free media outperforms serum-based media and maintains phenotype, with secondary suppliers for cytokines.
T-cells (1x106) were stimulated with CD3/CD28 Dynabeads® in both 6-well plates (5 ml) and a closed system breathable vessel
(35 ml) with di?erent media. The serum-free X-VIVO media supported the largest expansion of T-cells, comparable to RPMI
 supplemented with human serum in both open and closed systems and outperforming several serum-free media alternatives 

LONZA X-VIVO 15 已在美國FDA進行備案。 生產用X-VIVO 15培養(yǎng)基由擁有質量管理認證的歐洲或美國工廠生產，嚴格按照cGMP標準，不含抗生素、不含酚紅，且全部標記為FFM (For Further Manufacture)。用于科研及研發(fā)用途的X-VIVO 15培養(yǎng)基，添加抗生素及酚紅，并標記為RUO(Research Use Only)。

瑞士LONZA集團，在quan球擁有100余個生產基地和辦事處，quan球員工14500余人，是zhu名的生物技術、制藥、特殊成分供應商，多年來為基因治療研究、過繼免疫治療研究及其他細胞療法基礎研究開發(fā)了眾多研究工具。



LONZA X-VIVO 15 相關文獻     

1. Highly efficient therapeutic gene editing of human hematopoietic stem cells.(NatureMedicine,2019)
2. Bacteria-free minicircle DNA system to generate integration-free CAR-T cells.(J Med Genetics,2019,56: 10-17)
3. Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function.(Cell,2018,175(7):1985-1971)
4. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells.(Nature Medicine,2018,24(8): 1216-1224)
5. Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies. (Cancer Immunol Immunother,2018,67(1):25-38) 
6. Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium.(Molecular Therapy,2018,8:65-74)
7. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.(Cell,2018,173(6):1439-1453)
8. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.(Nature,2017,543(7643):113-117)
9. A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors.(Nature Genetics,2016,49(2):193-203)
10. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.(Leukemia,2017,31:2587-2593)
11. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. (OncoImmunology,2017,7(2))
12. A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors.(Nature Genetics,2016,49(2):193-203)